Results 81 to 90 of about 2,524 (195)

Dual Immunization Against RSV With RSVpreF and Nirsevimab

JAMA Pediatrics
This cohort study aimed to describe RSV-associated lower respiratory tract infection hospitalizations among infants in France who received both maternal RSV-preF vaccination and nirsevimab during the 2024-2025 RSV season.
Tréluyer, Ludovic, Bertrand, Marion, Gabet, Amélie, Jabagi, Marie-Joelle, Kolla, Epiphane, Olié, Valérie, Zureik, Mahmoud, Rachas, Antoine   +7 more
openaire   +2 more sources

Uneven Implementation of Nirsevimab Prophylaxis Resulted in Non-Uniform Reductions in RSV-Related Hospitalizations in Italy

Background/Objectives: Respiratory syncytial virus (RSV) bronchiolitis remains a leading cause of hospitalization in infants. In the 2024–2025 season, passive newborn immunization with nirsevimab, a long-acting anti-RSV monoclonal antibody, was ...
Enrico Valletta, Anthea Mariani, Claudio Cafagno, Désirée Caselli, Francesco Accomando, Claudia Rossini, Martina Fornaro, Giulia Marozzi, Melodie O. Aricò, Daniela Trotta, Letizia Lorusso, Maurizio Aricò   +11 more
core   +1 more source

The Efficacy and Safety of Nirsevimab in the Prevention of RSV Related Infections in Healthy Infants [PDF]

Objective: To assess the efficacy and safety of preventing Respiratory Syncytial virus (RSV) related respiratory illnesses and hospitalization with the use of Nirsevimab, as compared to placebo among infants among healthy early and late preterm infants ...
Mayo, Gabrielle, Ballard, Suyin
core  

Population Pharmacokinetics of Nirsevimab in Preterm and Term Infants

The Journal of Clinical Pharmacology
Abstract Nirsevimab, a monoclonal antibody with an extended half‐life, is approved for the prevention of respiratory syncytial virus (RSV) disease in all infants in Canada, the EU, Great Britain, and the USA. A population pharmacokinetics (PK) model was built to describe the PK of nirsevimab in preterm and term infants, and to ...
Lindsay Clegg, Ed Freshwater, Amanda Leach, Tonya Villafana, Ulrika Wählby Hamrén   +4 more
openaire   +2 more sources

Cost-Effectiveness Analysis of Clesrovimab for Respiratory Syncytial Virus in Infants in the United States

Vaccines
Background/Objectives: Respiratory syncytial virus (RSV) causes a significant hospitalization burden in infants. The objective of this study was to evaluate the cost-effectiveness of introducing clesrovimab, a recently approved long-acting monoclonal ...
Klodeta Kura, John C. Lang, Dawei Wang, Yoonyoung Choi, Michelle G. Goveia, Anushua Sinha, Yao-Hsuan Chen, Elamin H. Elbasha   +7 more
doaj   +1 more source

Safety and Efficacy of Nirsevimab in a Universal Prevention Program of Respiratory Syncytial Virus Bronchiolitis in Newborns and Infants in the First Year of Life in the Valle d’Aosta Region, Italy, in the 2023–2024 Epidemic Season

Vaccines
Respiratory syncytial virus (RSV) bronchiolitis remains a significant global health burden, particularly in newborns and infants during their first year of life.
Alessandra Consolati, Mariapaola Farinelli, Paolo Serravalle, Christine Rollandin, Laura Apprato, Susanna Esposito, Salvatore Bongiorno   +6 more
doaj   +1 more source

Potential Effects on Elderly People From Nirsevimab Use in Infants

Open Respiratory Archives
Nirsevimab therapy has the potential to revolutionize infant respiratory syncytial virus (RSV) prophylaxis. But other populations suffering RSV, such the elderly or those over 60, may also be protected by using this novel antibody in the infant group. It
Iván Sanz-Muñoz, Javier Castrodeza-Sanz, José M. Eiros   +2 more
doaj   +1 more source

CDC\u2019s Vaccines for Children Program Addendum : Special Considerations for Nirsevimab

Nirsevimab is an FDA-licensed monoclonal antibody that provides passive immunity against RSV-associated infection. On August 3, 2023, the Advisory Committee on Immunization Practices (ACIP) voted to recommend nirsevimab as an immunization for all infants

core  

Analysis of Beyfortus^® (Nirsevimab) Immunization Campaign: Effectiveness, Biases, and ADE Risks in RSV Prevention

Current Issues in Molecular Biology
Respiratory infections with respiratory syncytial virus (RSV) account for an important part of hospital admissions for acute respiratory infections. Nirsevimab has been developed to reduce the hospital burden of RSV infections.
Hélène Banoun
doaj   +1 more source

Estimating the economically justifiable price of nirsevimab versus standard of practice for the prevention of respiratory syncytial virus infections in neonates and infants in Spain: a cost–utility modelling study

BMJ Public Health
Introduction Respiratory syncytial virus (RSV) causes great morbidity and mortality among newborns. Nirsevimab represents a prophylactic alternative used in Spain for a universal prophylaxis strategy of all infants.
Miguel Angel Casado, Ruth Gil-Prieto, Jaime Pérez-Martín, Ariadna Díaz Aguiló, Samira Soudani, Leticia Platero-Alonso, Juan Luis López-Belmonte, Alberto de la Cuadra-Grande, Javier Álvarez Aldean   +8 more
doaj   +1 more source